- Previous Close
32.00 - Open
33.10 - Bid 32.60 x --
- Ask 33.95 x --
- Day's Range
32.00 - 33.10 - 52 Week Range
30.70 - 41.00 - Volume
50 - Avg. Volume
7,864 - Market Cap (intraday)
819.584M - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
18.60 - EPS (TTM)
1.72 - Earnings Date --
- Forward Dividend & Yield 1.65 (5.16%)
- Ex-Dividend Date Jul 26, 2024
- 1y Target Est
--
BioLASCO Taiwan Co., Ltd. provides bio-materials and surgical services in Taiwan and internationally. It breeds and produces SPF laboratory rats and mice, including outbreed stocks, inbreed strains, and immune deficient models, as well as offers special animal model services. The company also provides endotoxin detection, animal heath diagnostic, and serological kits, as well as biological indicators. In addition, it offers IVC systems and ventilated houses equipment; professional and automated animal watering systems; transponders; chlorine dioxide gas generators; mouse and rat tail cuff blood pressure systems, analgesia equipment, and animal behavioral equipment; metabolism and behavior systems, and trackers; XPERT cabinet X-ray systems; automatic cleaning equipment; workstations; isolation chambers; and foggers. BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.
www.biolasco.com.twRecent News: 6662.TWO
View MorePerformance Overview: 6662.TWO
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6662.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6662.TWO
View MoreValuation Measures
Market Cap
819.58M
Enterprise Value
764.07M
Trailing P/E
18.60
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.81
Price/Book (mrq)
1.82
Enterprise Value/Revenue
2.61
Enterprise Value/EBITDA
11.30
Financial Highlights
Profitability and Income Statement
Profit Margin
15.05%
Return on Assets (ttm)
5.88%
Return on Equity (ttm)
9.67%
Revenue (ttm)
292.5M
Net Income Avi to Common (ttm)
44.03M
Diluted EPS (ttm)
1.72
Balance Sheet and Cash Flow
Total Cash (mrq)
162.52M
Total Debt/Equity (mrq)
23.81%
Levered Free Cash Flow (ttm)
-7.41M